Cutaneous T-Cell Lymphoma (CTCL) Treatments

Find Cutaneous T-Cell Lymphoma (CTCL) Treatments

Brand Name

Valchlor

Generic Name

Mechlorethamine

View Brand Information

FDA approval date: November 08, 2018

Classification: Alkylating Drug

Form: Gel

What is Valchlor (Mechlorethamine)?

VALCHLOR is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy. VALCHLOR is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy .

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Who is this study for: Patients with Solid Tumors

Enrollment Status: Recruiting

Publish Date: April 15, 2026

Intervention Type: Drug

Study Drugs: Fludarabine, Cyclophosphamide, MESNA, B7-H3 CAR T cells

Study Phase: Phase 1

Summary: 3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.The purpose of this study is to find the ...

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Who is this study for: Patients with acute myelogenous leukemia

Enrollment Status: Recruiting

Publish Date: March 30, 2026

Intervention Type: Drug

Study Drugs: CD123-CAR T, Cyclophosphamide, Fludarabine, Mesna, Rituximab

Study Phase: Phase 1

Objective: * To determine the safety of one intravenous infusion of escalating doses of autologous, CD123-CAR T cells in patients (≤21 years) with recurrent/refractory CD123+ disease (AML/MDS, B-ALL, T-ALL or BPDCN) after lymphodepleting chemotherapy. * To determine the safety of an intravenous infusion of escalating doses of donor derived, CD123-CAR T cells in patients (≤21 years) with recurrent/refractory ...

N10: Reduced Therapy for High-Risk Neuroblastoma

Enrollment Status: Recruiting

Publish Date: February 10, 2026

Intervention Type: Biological, Drug

Study Phase: Phase 2

Summary: The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.

View All Clinical Trials

Related Latest Advances

Topical hypericin: a promising photodynamic therapy for early-stage cutaneous T-cell lymphoma.

Journal: Expert opinion on investigational drugs

Published: March 17, 2026

Development of a Novel Approach for In Vivo Tumor Hypoxia PET Imaging with Nitroreductase-Specific Responsive Radiotracers.

Journal: Molecular pharmaceutics

Published: February 18, 2026

Chlormethine gel use in mycosis fungoides: could contact dermatitis predict outcomes?

Journal: Italian journal of dermatology and venereology

Published: February 02, 2026

View All Latest Advances